Adial Pharmaceuticals Cash And Equivalents vs. Book Value Per Share
| ADIL Stock | USD 1.09 0.01 0.91% |
For Adial Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Adial Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Adial Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Adial Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Adial Pharmaceuticals over time as well as its relative position and ranking within its peers.
Adial |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adial Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.94) | Return On Assets (1.04) | Return On Equity (3.21) |
The market value of Adial Pharmaceuticals is measured differently than its book value, which is the value of Adial that is recorded on the company's balance sheet. Investors also form their own opinion of Adial Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Adial Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adial Pharmaceuticals' market value can be influenced by many factors that don't directly affect Adial Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adial Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adial Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Adial Pharmaceuticals Book Value Per Share vs. Cash And Equivalents Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Adial Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Adial Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Adial Pharmaceuticals is rated below average in cash and equivalents category among its peers. It is rated below average in book value per share category among its peers . The ratio of Cash And Equivalents to Book Value Per Share for Adial Pharmaceuticals is about 3,731,161 . At this time, Adial Pharmaceuticals' Book Value Per Share is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Adial Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Adial Book Value Per Share vs. Cash And Equivalents
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Adial Pharmaceuticals |
| = | 9.16 M |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Adial Pharmaceuticals |
| = | 2.46 X |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Adial Book Value Per Share Comparison
Adial Pharmaceuticals is currently under evaluation in book value per share category among its peers.
Adial Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Adial Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Adial Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Adial Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Adial Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Interest Income | 106.2 K | 111.6 K | |
| Operating Income | -6.9 M | -7.2 M | |
| Net Loss | -9.6 M | -10.1 M | |
| Income Before Tax | -7 M | -7.4 M | |
| Total Other Income Expense Net | -113.9 K | -119.6 K | |
| Net Loss | -17.5 M | -16.6 M | |
| Net Loss | -7 M | -7.4 M | |
| Income Tax Expense | -1.9 M | -1.8 M | |
| Net Interest Income | 106.2 K | 111.6 K | |
| Non Operating Income Net Other | 40.2 K | 42.3 K | |
| Change To Netincome | 6.8 M | 7.2 M | |
| Net Loss | (4.92) | (5.16) | |
| Income Quality | 0.97 | 0.51 | |
| Net Income Per E B T | 0.90 | 0.80 |
Adial Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Adial Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Adial Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Adial Pharmaceuticals' important profitability drivers and their relationship over time.
Use Adial Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adial Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adial Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Adial Pharmaceuticals Pair Trading
Adial Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Adial Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adial Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adial Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adial Pharmaceuticals to buy it.
The correlation of Adial Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adial Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adial Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adial Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Adial Pharmaceuticals position
In addition to having Adial Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Investment Grade ETFs Thematic Idea Now
Investment Grade ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Investment Grade ETFs theme has 263 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Investment Grade ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
To fully project Adial Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Adial Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Adial Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.